NUC-013/PSC
Research type
Research Study
Full title
Observational study to follow up clinical events in patients with primary sclerosing cholangitis (PSC) who had participated in the NUC-5 trial
IRAS ID
371042
Contact name
Palak Trivedi
Contact email
Sponsor organisation
DrFalk Pharma GmbH
Duration of Study in the UK
5 years, 10 months, 8 days
Research summary
This study is a non‑interventional, observational follow‑up of former participants of the NUC‑5/PSC phase III clinical trial. Its purpose is to assess the long‑term disease course and PSC‑related clinical events in patients with primary sclerosing cholangitis (PSC) over a period of up to 10 years after their baseline visit in the NUC‑5/PSC trial.
Only individuals who previously took part in NUC‑5/PSC and who are not enrolled in the NUT‑022/PSC interventional extension trial are eligible. Approximately 70 patients from around 40 former trial sites in Europe and the Russian Federation are expected to be included.After obtaining written informed consent from living patients, study personnel will collect data exclusively from existing medical records, with no study‑specific procedures, tests, or visits. For deceased patients, retrospective data collection will occur in line with applicable laws. The first data collection covers the interval from the participant’s last day in NUC‑5/PSC until the site’s first data‑collection point. Thereafter, annual chart reviews will capture new PSC‑related clinical events such as relevant strictures, carcinomas (CCC, HCC, CRC), transplant‑related outcomes, hepatic decompensation events, variceal bleeding, hepatic encephalopathy, and other predefined outcomes.All data will be entered into an electronic Case Report Form (eCRF) in pseudonymised form. Statistical analysis will be descriptive only, with interim analysis planned for 2026 and a final analysis at study completion.Overall, the study aims to generate meaningful real‑world evidence on long‑term PSC progression and complications among former NUC‑5/PSC participants.REC name
South Central - Hampshire B Research Ethics Committee
REC reference
26/SC/0271
Date of REC Opinion
4 Aug 2026
REC opinion
Favourable Opinion